WO2005018537A3 - Aptamere a oligonucleoside phosphorothioate et phosphorodithioate selectionne de maniere combinatoire et selon la structure pour le ciblage des facteurs de transcription ap-1 - Google Patents

Aptamere a oligonucleoside phosphorothioate et phosphorodithioate selectionne de maniere combinatoire et selon la structure pour le ciblage des facteurs de transcription ap-1 Download PDF

Info

Publication number
WO2005018537A3
WO2005018537A3 PCT/US2004/016246 US2004016246W WO2005018537A3 WO 2005018537 A3 WO2005018537 A3 WO 2005018537A3 US 2004016246 W US2004016246 W US 2004016246W WO 2005018537 A3 WO2005018537 A3 WO 2005018537A3
Authority
WO
WIPO (PCT)
Prior art keywords
transcription factors
structure based
aptamer targeting
phosphorodithioate
oligonucleoside phosphorothioate
Prior art date
Application number
PCT/US2004/016246
Other languages
English (en)
Other versions
WO2005018537A2 (fr
Inventor
David G Gorenstein
Bruce A Luxon
Norbert Herzog
Judith F Aronson
David Beasley
Allan Barret
Robert E Shope
Xian Bin Yang
Original Assignee
Univ Texas
David G Gorenstein
Bruce A Luxon
Norbert Herzog
Judith F Aronson
David Beasley
Allan Barret
Robert E Shope
Xian Bin Yang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, David G Gorenstein, Bruce A Luxon, Norbert Herzog, Judith F Aronson, David Beasley, Allan Barret, Robert E Shope, Xian Bin Yang filed Critical Univ Texas
Priority to CA002526853A priority Critical patent/CA2526853A1/fr
Priority to EP04776088A priority patent/EP1667729A4/fr
Publication of WO2005018537A2 publication Critical patent/WO2005018537A2/fr
Publication of WO2005018537A3 publication Critical patent/WO2005018537A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C12N2330/31—Libraries, arrays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12211—Phlebovirus, e.g. Rift Valley fever virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

L'invention concerne une composition et des procédés de fabrication et d'utilisation d'une banque combinatoire pour identifier les thioaptamères modifiés qui se lient à des facteurs de transcription tels que IL-6, NF-λB, AP-1 et analogue, et agissent sur la réponse immunitaire d'un animal hôte. L'invention concerne aussi une composition et des méthodes de traitement d'infections virales, ainsi que des vaccins et des adjuvants vaccinaux qui modifient les réponses immunitaires de l'hôte.
PCT/US2004/016246 2003-05-23 2004-05-20 Aptamere a oligonucleoside phosphorothioate et phosphorodithioate selectionne de maniere combinatoire et selon la structure pour le ciblage des facteurs de transcription ap-1 WO2005018537A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002526853A CA2526853A1 (fr) 2003-05-23 2004-05-20 Aptamere a oligonucleoside phosphorothioate et phosphorodithioate selectionne de maniere combinatoire et selon la structure pour le ciblage des facteurs de transcription ap-1
EP04776088A EP1667729A4 (fr) 2003-05-23 2004-05-20 Aptamere a oligonucleoside phosphorothioate et phosphorodithioate selectionne de maniere combinatoire et selon la structure pour le ciblage des facteurs de transcription ap-1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47288803P 2003-05-23 2003-05-23
US60/472,888 2003-05-23

Publications (2)

Publication Number Publication Date
WO2005018537A2 WO2005018537A2 (fr) 2005-03-03
WO2005018537A3 true WO2005018537A3 (fr) 2005-05-26

Family

ID=34215796

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/016246 WO2005018537A2 (fr) 2003-05-23 2004-05-20 Aptamere a oligonucleoside phosphorothioate et phosphorodithioate selectionne de maniere combinatoire et selon la structure pour le ciblage des facteurs de transcription ap-1

Country Status (3)

Country Link
EP (1) EP1667729A4 (fr)
CA (1) CA2526853A1 (fr)
WO (1) WO2005018537A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910523B2 (en) * 2003-05-23 2011-03-22 Board Of Regents, The University Of Texas System Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors
EP1877069A2 (fr) 2005-05-04 2008-01-16 Noxxon Pharma AG Nouvelle utilisation de spiegelmers
CA2760774A1 (fr) * 2009-05-05 2010-11-11 Altermune Technologies, Llc Immunite chimiquement programmable
JP6591392B2 (ja) * 2013-03-14 2019-10-16 ソマロジック, インコーポレイテッドSomaLogic, Inc. Ｉｌ−６に結合するアプタマー及びｉｌ−６介在性状態の治療または診断におけるそれらの使用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663153A (en) * 1994-03-25 1997-09-02 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
EP0855184A1 (fr) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Composition pharmaceutique comprenant un polynucléotide et un antigène notamment pour la vaccination
US20010034330A1 (en) * 1998-08-10 2001-10-25 Charlotte Kensil Innate immunity-stimulating compositions of CpG and saponin and methods thereof
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
US20030133229A1 (en) * 2002-01-14 2003-07-17 International Business Machines Corporation Microsuspension assemblies for direct access storage devices

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9303262B2 (en) * 2002-09-17 2016-04-05 Archemix Llc Methods for identifying aptamer regulators
EP1572978A4 (fr) * 2002-10-16 2006-05-24 Univ Texas Banques combinatoires d'aptameres a groupes phosphorothioate et phosphorodithioate oligonucleotidiques lies a des billes
US7910523B2 (en) * 2003-05-23 2011-03-22 Board Of Regents, The University Of Texas System Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors
WO2005037053A2 (fr) * 2003-05-23 2005-04-28 Board Of Regents - The University Of Texas System Recherche systematique a haut debit, dans des echantillotheques d'aptameres, de liaisons specifiques avec des proteines sur des virus et d'autres pathogenes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663153A (en) * 1994-03-25 1997-09-02 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
EP0855184A1 (fr) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Composition pharmaceutique comprenant un polynucléotide et un antigène notamment pour la vaccination
US20010034330A1 (en) * 1998-08-10 2001-10-25 Charlotte Kensil Innate immunity-stimulating compositions of CpG and saponin and methods thereof
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
US20030133229A1 (en) * 2002-01-14 2003-07-17 International Business Machines Corporation Microsuspension assemblies for direct access storage devices

Also Published As

Publication number Publication date
CA2526853A1 (fr) 2005-03-03
WO2005018537A2 (fr) 2005-03-03
EP1667729A4 (fr) 2007-10-17
EP1667729A2 (fr) 2006-06-14

Similar Documents

Publication Publication Date Title
WO2006091915A3 (fr) Oligonucleotides immunostimulateurs
WO2004016805A3 (fr) Acides nucléiques immunostimulants
WO2005032455A8 (fr) Oligonucleoside phosphorothioate selectionnes de maniere combinatoire et a base structurelle et facteurs de transcription ap-1 ciblant un phosphorodithioate aptamere
ES2206424T3 (es) Oligodesoxinucleotidos inmunoestimulantes.
MY165643A (en) 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP3424524A3 (fr) Nouvelles molécules d'acide nucléique
ATE426412T1 (de) Adjuvante influenza-vakzine
DK1355930T3 (da) Fremgangsmåde til identifikation, isolering og fremstilling af antigener mod et specifikt patogen
HN2006016512A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
WO2005028511A3 (fr) Anticorps anti-amyloides, compositions, procedes et utilisations
NO20015073L (no) Vaksiner
MY159370A (en) Semi-soft-class immunostimulatory oligonucleotides
DK1104306T3 (da) Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
IL226717A (en) Isolated nucleic acids encoded by anti-beta human antibodies 7
WO2009095226A3 (fr) Acides nucléiques de formule (i) (n<sb>u</sb>g<sb>l</sb>x<sb>m</sb>g<sb>n</sb>n<sb>v</sb>)<sb>a</sb> et leurs dérivés sous forme d'immunostimulant/adjuvant
WO2003059381A3 (fr) Préparations immunogènes et vaccins à base d'arn
DE60036698D1 (de) Chlamydia-antigene und entsprechende dna-fragmente und deren verwendungen
EP1220925B8 (fr) Antigenes de chlamydia , fragments d'adn correspondants et utilisations
ZA202207790B (en) Pharmaceutical composition and use thereof
WO2011007359A3 (fr) Vaccins anti-infection fondés sur plusieurs épitopes spécifiquews de l'antigène
WO2004005476A3 (fr) Compositions d'acide nucleique destinees a stimuler les reponses immunitaires
WO2005049832A3 (fr) Interference d'acides nucleiques specifiques a fcgriia
WO2004067567A3 (fr) Anticorps diriges contre le virus dengue, compositions, methodes et utilisations correspondantes
WO2005018537A3 (fr) Aptamere a oligonucleoside phosphorothioate et phosphorodithioate selectionne de maniere combinatoire et selon la structure pour le ciblage des facteurs de transcription ap-1
WO2005049647A3 (fr) Compositions et methodes de potentialisation de reponses immunitaires contre des antigenes cibles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2526853

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004776088

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004776088

Country of ref document: EP